Open AccessErythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma
Author(s) -
Erzsébet HorváthPuhó,
Marit M. Suttorp,
Henrik Frederiksen,
Tiny Hoekstra,
Olaf M Dekkers,
Lars Pedersen,
Suzanne C. Cannegieter,
Friedo W. Dekker,
Henrik Toft Sørensen
Publication year - 2018
Publication title -
clinical epidemiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.868
H-Index - 58
ISSN - 1179-1349
DOI - 10.2147/clep.s172306
Subject(s) - medicine , multiple myeloma , hazard ratio , lenalidomide , incidence (geometry) , myelodysplastic syndromes , epidemiology , stroke (engine) , proportional hazards model , confidence interval , bone marrow , mechanical engineering , physics , optics , engineering
Erythropoiesis-stimulating agent (ESA) treatment has been associated with an increased risk of venous thromboembolism (VTE) in patients with solid tumors and with an increased risk of cardiovascular events in patients with chronic kidney disease. The ESA-related risk in patients with hematological neoplasms remains unclear. We, therefore, aimed to assess the ESA-related risk of VTE, myocardial infarction (MI), and stroke in patients with multiple myeloma (MM) and myelodysplastic syndrome (MDS).